Literature DB >> 6188923

Intrinsic activity: partial agonists and partial antagonists.

E J Ariëns.   

Abstract

The effect of bioactive agents in many, if not most, cases should be considered as the result of an interaction among molecules of the active agent, the drug, and particular molecular sites of action, receptors (sometimes enzymes), in the biological object. In those cases in which a drug-receptor interaction is involved, two essential parameters should be distinguished, namely, the affinity of the active agent to its receptor, and the intrinsic activity of the active agent, i.e., the capacity to activate the receptors in the process of the drug-receptor interaction. Compounds that have only an affinity to particular types of receptors without an intrinsic activity will behave as blocking agents. Compounds may greatly differ in their affinity. Also, the capacity of bioactive agents to activate their specific receptors, the intrinsic activity, may differ for different compounds. These variations result in a differentiation among full agonists, partial agonists, partial antagonists, and full antagonists, which, besides, their affinity to the receptors, display a high, intermediate, low, and zero intrinsic activity, respectively, for the receptors. Examples of partial antagonists are the adrenergic blockers with intrinsic sympathomimetic activity. Various aspects of partial agonists and partial antagonists are discussed and elucidated.

Mesh:

Substances:

Year:  1983        PMID: 6188923

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

Review 1.  The applied pharmacology of beta-adrenoceptor antagonists (beta blockers) in relation to clinical outcomes.

Authors:  J D Fitzgerald
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 2.  Principles of pharmacotherapy: I. Pharmacodynamics.

Authors:  T J Pallasch
Journal:  Anesth Prog       Date:  1988 May-Jun

3.  Behavioural profile of partial D2 dopamine receptor agonists. 1. Atypical inhibition of d-amphetamine-induced locomotor hyperactivity and stereotypy.

Authors:  D Clark; L J Furmidge; N Petry; Z Y Tong; M Ericsson; D Johnson
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Suppression of cocaine- and food-maintained behavior by the D2-like receptor partial agonist terguride in squirrel monkeys.

Authors:  Donna M Platt; Joshua S Rodefer; James K Rowlett; Roger D Spealman
Journal:  Psychopharmacology (Berl)       Date:  2003-02-13       Impact factor: 4.530

5.  Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse.

Authors:  Matthew W Feltenstein; Phong H Do; Ronald E See
Journal:  Psychopharmacology (Berl)       Date:  2009-09-25       Impact factor: 4.530

6.  The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys.

Authors:  Cindy Achat-Mendes; Donna M Platt; Amy H Newman; Roger D Spealman
Journal:  Psychopharmacology (Berl)       Date:  2009-06-10       Impact factor: 4.530

Review 7.  Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.

Authors:  Hendrée E Jones; Sarah H Heil; Andjela Baewert; Amelia M Arria; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Gabriele Fischer
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

8.  Oleanolic acid acrylate elicits antidepressant-like effect mediated by 5-HT1A receptor.

Authors:  James O Fajemiroye; Prabhakar R Polepally; Narayan D Chaurasiya; Babu L Tekwani; Jordan K Zjawiony; Elson A Costa
Journal:  Sci Rep       Date:  2015-07-22       Impact factor: 4.379

9.  Antagonistic effect of dopamine structural analogues on human GABAρ1 receptor.

Authors:  Alfredo Alaniz-Palacios; Ataulfo Martínez-Torres
Journal:  Sci Rep       Date:  2017-12-12       Impact factor: 4.379

10.  Single high-dose buprenorphine for opioid craving during withdrawal.

Authors:  Jamshid Ahmadi; Mina Sefidfard Jahromi; Dara Ghahremani; Edythe D London
Journal:  Trials       Date:  2018-12-10       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.